Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
19.82(c) 20.33(c) 20.2(c) 20.5(c) 20.35 Last
2 337 647 1 211 434 992 158 1 177 693 913 526 Volume
-4.34% +2.57% -0.64% +1.49% -0.73% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 381 M - -
Net income 2021 201 M - -
Net cash position 2021 985 M - -
P/E ratio 2021 33,5x
Yield 2021 -
Sales 2022 1 636 M - -
Net income 2022 295 M - -
Net cash position 2022 1 212 M - -
P/E ratio 2022 21,2x
Yield 2022 -
Capitalization 6 411 M 6 411 M -
EV / Sales 2021 3,93x
EV / Sales 2022 3,18x
Nbr of Employees 773
Free-Float 98,0%
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ... 
Sector
Biotechnology & Medical Research
Calendar
09/29 | 02:40pmPresentation
More about the company
Ratings of Exelixis, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about EXELIXIS, INC.
09/20EXELIXIS : Reports Final Results From Phase 3 Trial of Thyroid Cancer Treatment
MT
09/20EXELIXIS : Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in ..
BU
09/20Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in..
CI
09/20EXELIXIS : Announces U.S. FDA Approval of CABOMETYX (cabozantinib) for Patients with Previ..
AQ
09/20EXELIXIS : Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patien..
AQ
09/20EXELIXIS : Truist Securities Adjusts Price Target on Exelixis to $36 From $37, Maintains B..
MT
09/18EXELIXIS : Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patien..
BU
09/18Exelixis, Inc. Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in..
CI
09/17EXELIXIS : Gets FDA's Approval for Cabometyx to Treat Thyroid Cancer -- Stock Up 3% After-..
MT
09/17EXELIXIS : Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Prev..
BU
09/17Exelixis, Inc. Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients wi..
CI
09/16EXELIXIS : Says New Exploratory Data from Late-Stage Trial Show Potential of Kidney Cancer..
MT
09/16EXELIXIS : Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Reg..
BU
09/16Exelixis, Inc Announces CABOMETYX in Combination with OPDIVO® Provides Efficacy Benefit..
CI
09/07EXELIXIS' : Chief Medical Officer Passes Away
MT
More news
News in other languages on EXELIXIS, INC.
09/20Exelixis annonce les résultats finaux de l'essai de phase 3 du traitement du cancer de ..
09/17Exelixis obtient l'approbation de la FDA pour Cabometyx dans le traitement du cancer de..
09/16Exelixis déclare que de nouvelles données exploratoires issues d'un essai de phase avan..
09/07Décès du médecin-chef d'Exelixis
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 20,50 $
Average target price 31,69 $
Spread / Average Target 54,6%
EPS Revisions
Managers and Directors
Michael M. Morrissey President, Chief Executive Officer & Director
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Dana T. Aftab Executive Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.2.14%6 459
GILEAD SCIENCES, INC.23.05%89 886
BIONTECH SE333.01%85 255
WUXI APPTEC CO., LTD.34.39%68 592
REGENERON PHARMACEUTICALS33.82%67 216
VERTEX PHARMACEUTICALS-21.68%48 018